

REFERENCES

1. Daya S. Evidence-based management of RPL: optimal diagnostic protocol. *International Congress Series*.2004; 1266: 318– 327.
2. Ford HB, Schust DJ. RPL: Etiology, Diagnosis, and Therapy. *Reviews in Obstetric and Gynecology*. 2009; Vol 2: 2
3. Walker ID, Greaves M, Preston FE. On behalf of the haemostasis and thrombosis task force British Committee for standards in haematology. Investigation and management of heritable thrombophilia. *Br J Haematology*. 2001; 114:512–528.
4. Resch B, Gallistl S, Kutschera J, et al. 2004. Thrombophilic polymorphisms—factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations—and preterm birth. *Wien Klin Wochenschr*.2004; 116:622–626.
5. Settin A, Elshazli R, Salama A, ElBaz R. Methylenetetrahydrofolate Reductase Gene Polymorphisms in Egyptian Women with Unexplained RPL. *Genet & mol biomarkers*.2011; Vol 00.
6. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. *Trends Pharmacol Sci*. 2001; 22:195–201.
7. Giovannetti E, Dewa G, Ugrasena G, Supriyadi E, Vroling L, Azzarello A. Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate

- synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia. *Leukemia Research*. 2008;32; 19–24
8. Botto, L.D. and Yang, Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. *Am. J. Epidemiol.* 2000;151, 862–877
 9. Bailey SW, Ayling JE. The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake. *National Academy of Sciences of the United States of America*. 2009; 106 (36): 15424–9.
 10. Weinstein, SJ. Null Association Between Prostate Cancer and Serum Folate, Vitamin B6, Vitamin B12, and Homocysteine. *Cancer Epidemiology, Biomarkers, & Prevent.* 2003 ; 12 (11): 1271–1272.
 11. Kamen B. Folate and antifolate pharmacology. *Seminars in oncology*. 1997; 24 (5 Suppl 18): S18–30–9.
 12. Hoffbrand AV, Weir DG. The history of folic acid. *Br J Haematol*. 2001; 113 (3): 579–589
 13. Finnell, R.H. Neural tube and craniofacial defects with special emphasis on folate pathway genes. *Crit. Rev. Oral Biol. Med.* 1998; 9, 38–53
 14. Ray JG, Laskin CA. Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: a systematic review. *Placenta*. 1999; 20,519–529

15. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. *TRENDS in Pharmacological Sciences*. 2001; Vol.22
16. Calle M, Usandizaga R, Sancha M. Homocysteine, folic acid and B-group vitamins in obstetrics and gynaecology. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2003; 107:125–134
17. Vilaseca MA, Moyano D, Ferrer I, Artuch R. Total homocysteine in pediatric patients. *Clin Chem*. 1997; 43:690–2.
18. Lo´pez-Quesada EL, Vilaseca MA, Gonza´lez S. Homociste´na y gestacio´n. *Med Clin Barc*. 2000; 115:352–6.
19. Picciano MF. Is homocysteine a biomarker for identifying women at risk of complications and adverse pregnancy outcomes. *Am J Clin Nutr*. 2000; 71:857–8.
20. Steegers-Theunissen RP, Wathen NC, Eskes TK, Van Raaj-Selten B, Chard T. Maternal and fetal levels of methionine and homocysteine in early human pregnancy. *Br J Obstet Gynecol*. 1997; 104:10–4.
21. Meegdes NHLM, Ingenhoes R, Peeters LLH, Exalto N. Early pregnancy wastage: relationship between chorionic vascularization and embryonic development. *Fertil Steril*. 1988; 49:216–20
22. Nelen WL, Bulten J, Steegers EA, Blom HJ, Hanselaar AG, Eskes TK. Maternal Homocysteine and chorionic vascularization in recurrent early pregnancy loss. *Hum Reprod*. 2000; 15:954–60.

23. Nelen WL, Blom HJ, Thomas CM, Steegers EA, Boers GH, Eskes TK. Methylentetrahydrofolate reductase polymorphism affects the change in homocysteine and folate concentrations resulting from low dose folic acid supplementation in women with unexplained RPLs. *J Nutr.*1998; 128:1336–41.
24. Brouwer IA, van Dusseldorp M, Thomas CMG, Duran M, Hautvast JGAJ, Eskes TKAB, Steegers-Theunissen RPM. Low-dose folic acid supplementation decreases plasma homocysteine concentrations: a randomized trial. *Am J Clin Nutr.* 1999; 69:99–104.
25. Carter CO. Clues to the aetiology of neural tube malformations. *Dev Med Child Neurol.* 1974; 16(Suppl 32):3–15.
26. Ho JJ. Folic acid in the prevention of Neural Tube Defect – Programme for Malaysia. *Med J Malaysia.* 2004; 59(1): 94-9.
27. Molloy AM, Weir DG, Scott JM. 1999. Homocysteine, folate enzymes and neural tube defects. *Haematologica.* 1999;84:53–6.
28. Dawson EB, Evans DR, Harris WA, Van Hook JW. Amniotic fluid B12, calcium, and lead levels associated with neural tube defects. *Am J Perinatol.*1999;16:373–8.
29. Gonzalez-Herreera L, Garcia-Escalante G, Zapata I. Frequency of the thermolabile variant C677T in the MTHFR gene and lack of the association with neural tube defects in the State of Yucatan, Mexico. *Clin Genetic.*2002; 62: 394-8.

30. Hayati AR, Zainal AI, Tan GC, Ong LC, Khoo TB. MTHFR C677T Polymorphism as a Risk Factor of Neural Tube Defects in Malay: A Case Control Study. *Med J Malaysia*. 2008; Vol 63.
31. Volcik KA, Shaw GM, Lammer E, Zhu H, Finnell R. Evaluation of infant methylenetetrahydrofolate reductase genotype, maternal vitamin use and risk of high versus low level spina bifida defects. *Birth Defects Research Part A: Clinical and Molecular Teratology*. 2003; 67(3): 154-7
32. Botto L, Moore C, Khoury M, Erickson JD. Neural tube defects. *N Engl J Med*. 1999; 341(20): 1509-19.
33. Cigliero SS, Fabiani C, Boccato CM. C677T mutation in MTHFR: population data in Friuli-Venezia Giulia (North-East Italy). *Forensic Science International: Genetics Supplement Series*. 2011; 3: e295-e296.
34. Sadewa AH, Sunarti, Sutomo R. The C677T mutation in the methylenetetrahydrofolate reductase gene among the Indonesian Javanese population. *Kobe J Med Sci*. 2002; Vol 48: 137-144.
35. Mutchnick OM, Lopez MA, Luna L, Waxman J and Babinsky VE. High prevalence of the thermolabile methylenetetrahydrofolate reductase variant in Mexico: a country with very high prevalence of neural tube defects. *Mol Genet Metab*. 1999; 68:461-67.
36. Van der Put NMJ, Steegers RPM, Frosst P. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. *Lancet*; 1995; 346: 1070-1071.

37. Misra UK, Kalita J, Srivastava AK. MTHFR gene polymorphism and its relationship with plasma homocysteine and folate in a North Indian Population. *Biochem Genet.* 2010; 48:229-235.
38. Wu X, Zhao L, Zhu H, He D, Tang W, Luo Y. Association between the MTHFR C677T polymorphism and recurrent pregnancy loss: a meta-analysis. *Genet Test Mol Biomarkers.* 2012; 16(7):806-11
39. Biswas A, Choudhry P, Mittal A. Recurrent abortions in Asian Indians: no role of factor V Leiden Hong Kong/ Cambridge mutation and MTHFR polymorphism. *Clin Appl Thromb Hemost.* 2008;14:102–104
40. Cardona H, Cardona-Maya W, Go´mez JG. Relationship between methylenetetrahydrofolate reductase polymorphism and homocysteine levels in women with RPL: a nutrigenetic perspective. *Nutr Hosp.* 2008; 23:277–282
41. Zahed LF, Rayes RF, Mahfouz RA. Prevalence of factor V Leiden, prothrombin and methylene tetrahydrofolate reductase mutations in women with adverse pregnancy outcomes in Lebanon. *Am J Obstet Gynecol.* 2006; 195:1114–1118.
42. Pauer HU, Voigt-Tschirschwitz T, Hinney B. Analyzes of three common thrombophilic gene mutations in German women with recurrent abortions. *Acta Obstet Gynecol Scand.*2003; 82:942–947.
43. Carp H, Salomon O, Seidman D, Dardik R. Prevalence of genetic markers for thrombophilia in RPL. *Hum Reprod.* 2002; 17:1633–1637.